JNJ/PTGX: JNJ2113: Icotrokinra ANTHEM-Ulercative Colitis efficacy similar to oral competitors

Despite headline efficacy in PTGX/JNJ's ulcerative colitis phase 2 ANTHEM-UC at its highest dose, the initial efficacy appears similar to that of already FDA-approved orals and other oral classes in development. With limited safety and patient characteristic disclosure...